FILTER
FILTERED ARTICLE RESULTS
The Battery Material Supply Chain
February 15, 2022
How the mining sector will play a pivotal role in determining the world's climate change and green revolution outcomes.
Industry Thoughts on Battery Metals
February 15, 2022
Ontario’s battery metal juniors share their opinions.
The Global Tailings Standard
April 16, 2021
The mining industry and investment community are collaborating to mitigate a perpetual risk, after a series of high-profile disasters.
Tailings Management
April 16, 2021
Expert Opinion Article by Dan Etheredge, General Manager, Klohn Crippen Berger S.A.
Canada, Light at the End of the Tunnel
February 05, 2021
Rising metals prices and industry resilience have helped miners weather the storm.
Covid-19: Insights from Québec
May 12, 2020
The impact felt by the Exploration, Aviation and Natural Gas sectors in “La Belle Province”.
Toronto: The Home of Mining Finance
March 24, 2020
"While the incredible 2019 performance of a small section of the industry is an encouraging sign moving forward and should attract some investor confidence, a lack of new listings and the continued struggles of the junior community to attract finance have created a chasm between those who produce, and those who explore.”
The Battery Metal Supply Chain
February 27, 2020
North American collaboration in the effort to catch up with China.
Golden Opportunities: Juniors Hunt for Québec’s Next Major Deposit
April 26, 2019
In the face of challenging financial conditions, Québec’s juniors are finding strategies to drive their projects forward.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENTLY PUBLISHED
United States Life Sciences 2023
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
